UroGen Pharma Ltd. (URGN) announced on Tuesday the results from a long-term follow-up study involving their FDA-approved treatment, Jelmyto, designed for low-grade upper tract urothelial cancer in adults.
In the OLYMPUS trial, which included 71 participants, 41 patients achieved a complete response following primary chemoablation therapy with Jelmyto. These patients exhibited a median response duration of 47.8 months, with a median follow-up period of 28.1 months.
As of now, UroGen's stock is priced at $12.19 on the Nasdaq, reflecting a decline of 2.32 percent.
